Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer

被引:144
|
作者
Seppenwoolde, Y [1 ]
De Jaeger, K [1 ]
Boersma, LJ [1 ]
Belderbos, JSA [1 ]
Lebesque, JV [1 ]
机构
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2004年 / 60卷 / 03期
关键词
radiation pneumonitis; NTCP; lung cancer; radiotherapy;
D O I
10.1016/j.ijrobp.2004.04.037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study regional differences in lung radiosensitivity by evaluating the incidence of radiation pneumonitis (RP) in relation to regional dose distributions. Methods and Materials: Registered chest CT and single photon emission CT lung perfusion scans were obtained in 106 patients before curative or radical radiotherapy for non-small-cell lung cancer. The mean lung dose (MLD) was calculated. The single photon-emission CT perfusion data were used to weigh the MLD with perfusion, resulting in the mean perfusion-weighted lung dose. In addition, the lungs were geometrically divided into different subvolumes. The mean regional dose (MRD) for each region was calculated and weighted with the perfusion of each region to obtain the mean perfusion-weighted regional dose. RP was defined as respiratory symptoms requiring steroids. The incidence of RP for patients with tumors in a specific subvolume was calculated. The normal tissue complication probability (NTCP) parameter values for the TD50, and an offset NTCP parameter for tumor location were fitted for both lungs and for each lung subvolume to the observed data using maximum likelihood analysis. Results: The incidence of RP correlated significantly with the MLD and MRD of the posterior, caudal, ipsilateral, central, and peripheral lung subvolumes (p between 0.05 and 0.002); no correlation was seen for the anterior, cranial, and contralateral regions Similarly, a statistically significant correlation was observed between the incidence of RP and the perfusion-weighted MLD and perfusion-weighted MRD for all regions, except the anterior lung region. For this region, the dose-effect relation improved remarkably after weighting the local dose with the local perfusion. A statistically significant difference (p = 0.01) in the incidence of RP was found between patients with cranial and caudal tumors (11% and 40%, respectively). Therefore, a dose-independent offset NTCP parameter for caudal tumors was included in the NTCP model, improving most correlations significantly, confirming that patients with caudal tumors have a greater probability of developing RP. Conclusion: The incidence of RP correlated significantly with the MLD and MRD of most lung regions, except for the anterior, cranial, and contralateral regions. Weighting the local dose with the local perfusion improved the dose-effect relation for the anterior lung region. Irradiation of caudally located lung tumors resulted in a greater risk of RP than irradiation of tumors located in other parts of the lungs. (C) 2004 Elsevier Inc.
引用
收藏
页码:748 / 758
页数:11
相关论文
共 50 条
  • [1] Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer
    Gopal, R
    Starkschall, G
    Tucker, SL
    Cox, JDC
    Liao, ZX
    Hanus, M
    Kelly, JF
    Stevens, CW
    Komaki, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01): : 114 - 120
  • [2] Current landscape of palliative radiotherapy for non-small-cell lung cancer
    Jumeau, Raphael
    Vilotte, Florent
    Durham, Andre-Dante
    Ozsahin, Esat-Mahmut
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S192 - S201
  • [3] Risk Stratification by Combination of Heart and Lung Dose in Locally Advanced Non-Small-Cell Lung Cancer after Radiotherapy
    Watanabe, Yui
    Koide, Yutaro
    Shimizu, Hidetoshi
    Aoyama, Takahiro
    Shindo, Yurika
    Hashimoto, Shingo
    Tachibana, Hiroyuki
    Kodaira, Takeshi
    CANCERS, 2024, 16 (19)
  • [4] Radiotherapy and targeted therapies in non-small-cell lung cancer
    Girard, N.
    Mornex, F.
    BULLETIN DU CANCER, 2009, 96 (03) : 311 - 319
  • [5] Clinical Outcome of Stage III Non-small-cell Lung Cancer Patients After Definitive Radiotherapy
    Tatsuya Nakamura
    Nobukazu Fuwa
    Takeshi Kodaira
    Hiroyuki Tachibana
    Takuya Tomoda
    Rie Nakahara
    Haruo Inokuchi
    Lung, 2008, 186 : 91 - 96
  • [6] Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy
    Nakamura, Tatsuya
    Fuwa, Nobukazu
    Kodaira, Takeshi
    Tachibana, Hiroyuki
    Tomoda, Takuya
    Nakahara, Rie
    Inokuchi, Haruo
    LUNG, 2008, 186 (02) : 91 - 96
  • [7] The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy
    Yoon, SM
    Hong, YC
    Park, HJ
    Lee, JE
    Kim, SY
    Kim, JH
    Lee, SW
    Park, SY
    Lee, JS
    Choi, EK
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (03): : 885 - 891
  • [8] Clinical evaluation of proton radiotherapy for non-small-cell lung cancer
    Shioyama, Y
    Tokuuye, K
    Okumura, T
    Kagei, K
    Sugahara, S
    Ohara, K
    Akine, Y
    Ishikawa, S
    Satoh, H
    Sekizawa, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01): : 7 - 13
  • [9] Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer
    Bernstein, ED
    Herbert, SM
    Hanna, NH
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (03) : 291 - 301
  • [10] High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer
    Allena, Aaron M.
    Shochat, Tzippy
    Flex, Dov
    Kramer, Mordechai R.
    Zer, Alona
    Peled, Nir
    Dudnik, Elizabeta
    Fenig, Eyal
    Saute, Milton
    ONCOLOGY, 2018, 95 (01) : 13 - 19